Masimo Corporation
NASDAQ:MASIMedical - Devices
+$0.00 today
- Market cap
- $9.42B
- Beta
- 1.10
- P/E (TTM)
- 123.1
- EPS (TTM)
- $1.46
Volume 0.00M
Average 1.08M
MASI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Masimo CorporationNASDAQ: MASI
Research & Development · Q1 FY2026 · quarter ended Apr 2026
Research & development declines year over year
Q1 FY2026 research & development of $30M fell 11.5% year over year, ahead of the -38.4% change in trailing-twelve-month research & development. Sequentially, it fell 6.5% from the prior quarter. Over 3 fiscal years it compounded at -12.9% a year.
Context
- Research & development amounted to 8.3% of revenue in FY2025, down 2.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -11.5% holds above the trailing-twelve-month pace of -38.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 126.4M USD
- Year-over-year change
- -43.3%
- 4-year CAGR
- -2.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-03 | 126.4M | -43.3% |
| FY2024 | 2024-12-28 | 222.8M | +27.2% |
| FY2023 | 2023-12-31 | 175.2M | -8.5% |
| FY2022 | 2022-12-31 | 191.4M | +39.5% |
| FY2021 | 2021-12-31 | 137.2M | — |
Research & Development vs competitors
How MASI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -38.4% is the lowest of 7, against a peer median of +6.6%.
- Research & development amounts to 7.9% of revenue for MASI, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $512M USD | -16.6% | +4.8% | 4.5% | |
| LTM Jun 2026 | $325.34M USD | — | — | 8.3% | |
| LTM Jun 2026 | $261.1M USD | -14.3% | +0.0% | 10.1% | |
| LTM Sep 2026 | $179.67M USD | +7.9% | +15.5% | 64.0% | |
| FY2025 | €177.76M EUR | +21.3% | +54.4% | — | |
| LTM Apr 2026 | $122.5M USD | -38.4% | -12.9% | 7.9% | |
| LTM Jun 2026 | $55.23M USD | +14.4% | +7.2% | 7.0% | |
| LTM Jun 2026 | €25.44M EUR | +5.3% | -10.8% | 2.1% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MASI) | — | +6.6% | +6.0% | 4.5% | |
Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.24B | 2.04B | 2.05B | 2.09B | 1.53B |
| Cost of Revenue | 430.8M | 977M | 1.04B | 1.09B | 581.7M |
| Gross Profit | 808.4M | 1.06B | 1B | 1B | 945.2M |
| Gross Margin | 65.2% | 52.0% | 49.0% | 48.0% | 61.9% |
| Research & Development | 137.2M | 191.4M | 175.2M | 222.8M | 126.4M |
| Selling, General & Admin | 395.4M | 657.4M | 664M | 743.8M | 506M |
| Operating Expenses | 532.6M | 848.8M | 867M | 1.27B | 632.4M |
| Depreciation & Amortization | 35.6M | 136.1M | 98.3M | 103M | 38.8M |
| EBITDA | 310.3M | 355.2M | 236.7M | (158.7M) | 344.6M |
| EBITDA Margin | 25.0% | 17.4% | 11.6% | -7.6% | 22.6% |
| Operating Income | 275.8M | 210M | 136.5M | (266.7M) | 312.8M |
| Operating Margin | 22.3% | 10.3% | 6.7% | -12.7% | 20.5% |
| Interest Income | 900K | 1.8M | 3M | 4.8M | 3.4M |
| Interest Expense | 300K | 25.7M | 50.3M | 43.6M | 33.2M |
| Other Income / Expenses | (1.4M) | (16.6M) | (48.4M) | (38.6M) | (40.2M) |
| Income Before Tax | 274.4M | 193.4M | 88.1M | (305.3M) | 272.6M |
| Pre-Tax Margin | 22.1% | 9.5% | 4.3% | -14.6% | 17.9% |
| Income Tax Expense | 44.8M | 49.9M | 6.6M | (400K) | 64.9M |
| Net Income | 229.6M | 143.5M | 81.5M | (304.9M) | (151.5M) |
| Net Margin | 18.5% | 7.0% | 4.0% | -14.6% | -9.9% |
| EPS (Basic) | 4.16 | 2.68 | 1.54 | (5.72) | (2.83) |
| EPS (Diluted) | 3.98 | 2.60 | 1.51 | (5.72) | (2.80) |
| Weighted Avg Shares | 55.17M | 53.6M | 52.8M | 53.3M | 53.6M |
| Weighted Avg Shares (Diluted) | 57.68M | 55.2M | 54.1M | 53.3M | 54.2M |
Masimo Corporation
NASDAQ:MASI
Intrinsic Alpha fair value
Locked
Current Price
$179.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.